Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study - Fasching, Peter; Decker, T.; Guderian, G.; Heim, J.; Jackisch, C.; Lueck, H-J.; Lueftner, D.; Marme, F.; Reimer, T.; Woeckel, A. (ANNALS OF ONCOLOGY, 2018)
CRIS-Team WoS Importer:2019-03-08